Hancock Whitney Corp Cytom X Therapeutics, Inc. Transaction History
Hancock Whitney Corp
- $3.07 Billion
- Q3 2024
Shares
3 transactions
Others Institutions Holding CTMX
# of Institutions
72Shares Held
49.4MCall Options Held
112KPut Options Held
8.3K-
Tang Capital Management LLC San Diego, CA7.81MShares$6.56 Million0.79% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$4.39 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.16MShares$4.34 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X04.81MShares$4.04 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA3.1MShares$2.6 Million0.01% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $55.4M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...